Donald A. Bergstrom - Jun 24, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as attorney-in-fact
Stock symbol
RLAY
Transactions as of
Jun 24, 2022
Transactions value $
-$147,330
Form type
4
Date filed
6/28/2022, 05:53 PM
Previous filing
May 2, 2022
Next filing
Jul 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $33K +8K +8.65% $4.12 100K Jun 24, 2022 Direct F1, F2
transaction RLAY Common Stock Sale -$160K -8K -7.96% $20.00 92.5K Jun 24, 2022 Direct F1, F2
transaction RLAY Common Stock Sale -$20.3K -999 -1.08% $20.31 91.5K Jun 27, 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -8K -4.29% $0.00 178K Jun 24, 2022 Common Stock 8K $4.12 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2 Includes 87,141 shares underlying restricted stock units ("RSUs").
F3 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of RSUs on June 26, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F4 Includes 84,953 shares underlying RSUs.
F5 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.